Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma
1998/01/01 by John H. Sampson, James H. Carter, James Carter +2 · 25 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Cutaneous Melanoma Detection and Management #Brain Metastases and Treatment #Melanoma and MAPK Pathways
paper · doi:10.3171/jns.1998.88.1.0011
Abstract
UNLABELLED: Brain metastases are a common and devastating complication in patients with malignant melanoma. Therapeutic options for these patients are limited, and the prognosis is usually poor. OBJECT: A retrospective review of 6953 patients with melanoma treated at a single institution was undertaken to identify demographic factors associated with the development of clinically significant brain metastases in 702 of these patients and to determine the factors influencing the prognosis of this population to permit more informed recommendations regarding surgical therapy. METHODS: Factors found to be associated with the development of brain metastases included male gender, primary lesions located on mucosal surfaces or on the skin of the trunk or head and neck, thick or ulcerated primary lesions, and histological findings of acral lentiginous or nodular lesions. The overall median survival time of all patients with brain metastases was 113.2 days, and these metastases contributed to the death of 94.5% of the patients in this group. Patients with primary lesions located in the head or neck region had a significantly shorter survival time relative to other patients with brain metastases, whereas patients with a single brain metastasis, patients without lung or multiple other visceral metastases, and patients whose initial presentation with melanoma included a brain metastasis had a significantly better prognosis. The small group of patients who survived for more than 3 years was characterized by the presence of a surgically treated, single brain metastasis in the absence of other visceral metastatic disease. CONCLUSIONS: Although most patients with brain metastases resulting from melanoma have a dismal prognosis, some who are likely to survive for longer periods can be identified. In these patients surgical resection can significantly prolong meaningful survival. The decision to recommend surgery should be based primarily on the resectability of the brain metastases and on the status and number of other organs with metastatic lesions.
Cited by
- Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. [europepmc]
- Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain. [europepmc]
- Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. [europepmc]
- Successful treatment of melanoma brain metastases with adoptive cell therapy. [europepmc]
- Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. [europepmc]
- The evolving role of radiation therapy in the management of malignant melanoma. [europepmc]
- Whole brain radiotherapy after local treatment of brain metastases in melanoma patients--a randomised phase III trial. [europepmc]
- Why does Jack, and not Jill, break his crown? Sex disparity in brain tumors. [europepmc]
- Surgery for distant melanoma metastasis. [europepmc]
- Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. [europepmc]
- Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. [europepmc]
- Oncolytic myxoma virus: the path to clinic. [europepmc]
- Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. [europepmc]
- Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. [europepmc]
- Ipilimumab and whole brain radiation therapy for melanoma brain metastases. [europepmc]
- Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. [europepmc]
- Melanoma Brain Metastasis: Mechanisms, Models, and Medicine. [europepmc]
- Melanoma central nervous system metastases: current approaches, challenges, and opportunities. [europepmc]
- Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. [europepmc]
- Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. [europepmc]
- Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies. [europepmc]
- Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. [europepmc]
- MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors. [europepmc]
- Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. [europepmc]
- Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies. [europepmc]
Related